Lilly Eli & Co (NYSE:LLY) Big Money Sentiment Is 1.1

May 17, 2018 - By Sergio Grout

Eli Lilly and Company (NYSE:LLY) Corporate Logo

Lilly Eli & Co’s Sentiment

In Q4 2017 Lilly Eli & Co (NYSE:LLY) big money sentiment increased to 1.1, SEC filings reveal. That’s up 0.21, from 2017Q3’s 0.89. 463 active investment managers started new or increased holdings, while 422 sold and trimmed stock positions in Lilly Eli & Co so the sentiment improved. These funds own 827.08 million shares, that’s down from 827.83 million shares in 2017Q3. Funds holding Lilly Eli & Co in top 10 changed to 15 from 19 for a decrease of 4. In total 42 funds closed positions, 380 reduced and 346 increased. Also 117 funds bought new Lilly Eli & Co stakes.

Largest Lilly Eli & Co Shareholders

As of Q4 2017 Lilly Endowment Inc has 100% invested in Lilly Eli & Co. Lilly Eli & Co’s shareholder Private Capital Advisors Inc. owns 385,549 shares as of Q4 2017. Also, Weatherly Asset Management L. P. reported 327,825 shares in Lilly Eli & Co equivalent to 6.69% of its long stock exposure. Healthinvest Partners Ab revealed 32,000 shares position in Lilly Eli & Co. The New York-based fund Valueworks Llc looks positive on Lilly Eli & Co, having 69,752 shares.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide.The firm is worth $82.86 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products.Currently it has negative earnings. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

LLY is hitting $81.18 during the last trading session, after decreased 0.57%.Currently Eli Lilly and Company is downtrending after 10.19% change in last May 17, 2017. LLY has also 3.61M shares volume. The stock underperformed the S&P 500 by 21.74%.

Earnings report for Eli Lilly and Company (NYSE:LLY) is awaited on July, 24., Zacks reports. Last year’s earnings per share was $1.11, while now analysts expect change of 20.72 % up from current $1.34 earnings per share. The profit will be $1.37 billion for LLY if $1.34 earnings per share becomes true. 0.00 % EPS growth is what analysts predict. $1.34 earnings per share was published for last quarter.

National Pension Serv accumulated 823,494 shs. Arrow Financial Corporation holds 0.11% of its capital in Eli Lilly and Company (NYSE:LLY) for 5,505 shs. Koshinski Asset Mgmt Inc stated it has 7,644 shs. Menta Cap Ltd Liability Corporation invested 0.23% of its capital in Eli Lilly and Company (NYSE:LLY). Pictet Asset Mngmt Limited accumulated 1.11M shs or 0.24% of the stock. Oppenheimer Asset Mgmt, New York-based fund reported 314,594 shs. Private Ocean Lc invested in 0.05% or 1,049 shs. Huntington Bancorp holds 0.24% of its capital in Eli Lilly and Company (NYSE:LLY) for 178,627 shs. M&R Cap accumulated 2,441 shs or 0.05% of the stock. Front Barnett Assocs Limited Liability reported 0.05% of its capital in Eli Lilly and Company (NYSE:LLY). Advsrs Asset has invested 0.17% in Eli Lilly and Company (NYSE:LLY). 21,265 were reported by Stadion Money Limited Company. Fincl Bank Of Nova Scotia accumulated 510,011 shs or 0.2% of the stock. Nelson Van Denburg Campbell Wealth Mgmt Group Ltd Co invested in 6,653 shs or 0.13% of the stock. Valley Advisers Inc reported 11,336 shs.

Eli Lilly and Company had 11 insider sales and 0 buys since December 11, 2017. This’s net activity of $48.49 million. On Wednesday, April 25 LILLY ENDOWMENT INC had sold 180,000 shs worth $14.55M. Zakrowski Donald A had sold 876 shs worth $67,934. Smiley Joshua L sold 3,000 shs worth $237,600. $1.81M worth of Eli Lilly and Company (NYSE:LLY) was sold by Mahony Susan.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

A total of 10 analysts rate Eli Lilly (NYSE:LLY) as follows: 4 “Buy”, 5 “Hold” and 1 “Sell”. Тherefore 40% are bullish. The firm has $105.0 highest and $74 lowest target. The avg target $90.50 is 11.48% above the last ($81.18) price. (NYSE:LLY) has 17 ratings reports on 17 May 2018 according to StockzIntelligence. On Friday, March 23 the stock has “Buy” rating by Jefferies. On Tuesday, January 16 the firm has “Buy” rating by Jefferies given. On Friday, January 5 the stock of Eli Lilly and Company (NYSE:LLY) earned “Buy” rating by Argus Research. On Thursday, February 1 the stock of Eli Lilly and Company (NYSE:LLY) has “Hold” rating given by Leerink Swann. On Monday, February 26 the firm has “Buy” rating by Jefferies given. On Wednesday, December 13 the stock of Eli Lilly and Company (NYSE:LLY) earned “Hold” rating by Leerink Swann. The stock rating was downgraded by Credit Suisse to “Underperform” on Monday, January 22. On Friday, April 13 the firm has “Buy” rating given by Jefferies. On Tuesday, November 21 the rating was maintained by Morgan Stanley with “Equal-Weight”. On Thursday, February 1 the company was maintained by Bank of America.

For more Eli Lilly and Company (NYSE:LLY) news published recently go to: Benzinga.com, Streetinsider.com, 247Wallst.com, Streetinsider.com or Streetinsider.com. The titles are as follows: “Upcoming Earnings: CAT, LLY And BA Report This Week” published on April 23, 2018, “Eli Lilly & Co. (LLY) Says Data at ASCO Illustrate Patient-Driven Advances in Cancer Care” on May 16, 2018, “Will the FDA Shoot Down Eli Lilly and Incyte Again?” with a publish date: April 20, 2018, “Lilly (LLY) Says Galcanezumab Met Primary Endpoint in Phase 3 Study for Prevention of Episodic Cluster Headache” and the last “Lilly (LLY) to Acquire ARMO BioSciences (ARMO) for $50/Share” with publication date: May 10, 2018.

Eli Lilly and Company (NYSE:LLY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: